CTRI/2019/01/016844
已完成
4 期
A Prospective, Multicenter, Post-marketing Surveillance to Assess Safety & Efficacy of Perampanel in Indian Patients as an Adjunctive Treatment inPartial Onset Seizures with or Without Secondary Generalized Seizures in Patients with Epilepsy Aged 12 years or older.
Eisai Pharmaceutical India Limited0 个研究点目标入组 200 人待定
概览
- 阶段
- 4 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Health Condition 1: G401- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
- 发起方
- Eisai Pharmaceutical India Limited
- 入组人数
- 200
- 状态
- 已完成
- 最后更新
- 4年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. Male or female patients age greater than or equal to 12 years at the time of informed
- •2\. Patients prescribed perampanel for the adjunctive treatment of partial onset seizures
- •based on independent clinical judgment of treating physicians.
- •3\. Patients who provide informed consent to the treating physician.
排除标准
- •1\. Participation in another study involving administration of an investigational drug or
- •device whilst participating in this observational study
- •2\. Hypersensitivity \[allergic] to perampanel
结局指标
主要结局
未指定
相似试验
进行中（未招募）
4 期
A post marketing study to monitor safety of Abiraterone Acetate (Zytiga) in Indian patients with Prostate CancerHealth Condition 1: null- Indian participants with metastatic, castration-resistant prostate cancer will be enrolled in this study.CTRI/2016/04/006854Johnson Johnson Private Limited
尚未招募
4 期
Post marketing surveillance of Aripiprazole tabletHealth Condition 1: F209- Schizophrenia, unspecifiedCTRI/2022/01/039860Torrent Pharmaceuticals Limited
进行中（未招募）
1 期
Post marketing surveillance to collect safety information after vaccination with Bexsero administered in routine care and according to prescribing information in Korea.The study will collect real-world post-vaccination adverse events.EUCTR2023-000765-14-Outside-EU/EEAGlaxoSmithKline Biologicals SA
已完成
4 期
Superia: Sirolimus Eluting Coronary Stent System (SSECSS) India Post Marketing RegistryCTRI/2012/01/002393Innvolution Med System200
已完成
4 期
Postmarketingstudy to monitor safety of golimumab injection 50milligram (mg) in Indian subjects with Rheumatoid Arthritis (RA)Health Condition 1: null- Indian participants with Rheumatoid Arthritis will be enrolled in the studyCTRI/2016/04/006867Johnson Johnson Private Limited120